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Abstract
Background: It has been shown that transthyretin (TTR) exists in different molecular variants.
Besides point mutations associated with different diseases such as amyloidosis, other
posttranslational modifications occur that might be of diagnostic interest.
Results: TTR levels as determined by ELISA in plasma and urine of healthy individuals were 489 ±
155 µg/ml plasma and 46 ± 24 ng/g creatinine, respectively. Average levels in urine of pregnant
women were 45 ± 65 µg/g creatinine. The molecular heterogeneity of TTR was analyzed using a
high-throughput mass spectrometric immunoassay system. TTR was extracted from plasma or
urine onto an antibody-coated (via protein A) affinity chip surface (PS20) using the surface-
enhanced laser desorption/ionization (SELDI) technique. Subsequently samples were subjected to
time-of-flight mass spectrometry (TOF-MS). In healthy individuals, TTR in plasma occurred rather
consistently in two variants of 13732 ± 12 and 13851 ± 9 Da for the native and S-cysteinylated
forms and at a smaller signal of 14043 ± 17 Da for the S-glutathionylated form. In urine of pregnant
women, various signals were observed with a dominant signal at 13736 ± 10 Da and a varying
number of smaller immunoreactive fragments. These fragments are possibly the consequence of
metabolism in plasma or kidney.
Conclusion: This chip-based approach represents a rapid and accurate method to characterize
the molecular variants of TTR including protein or peptide fragments which are either related to
TTR or have resulted from its catabolism. These molecular variants may be of diagnostic
importance as alternative or novel biomarkers due to their predominant relation to the TTR
metabolism both in healthy and diseased individuals.
Background
Transthyretin (TTR, formerly called prealbumin) belongs
to a group of proteins including thyroxine-binding globu-
lin and albumin which bind and transport thyroid hor-
mones in the blood. It is a single polypeptide chain of 127
amino acids (14 kDa) and is present in the plasma as a
tetramer of non-covalently bound monomers. The major
sites of TTR synthesis are the liver and choroid plexus [1-
3]. Under physiological conditions, the macromolecular
complex plays an important physiological role in vitamin
A homeostasis because it binds the specific transport pro-
tein for retinol, the lipocalin retinol-binding protein
(RBP) [4,5]. This reduces the glomerular filtration of the
low molecular weight transport protein (21 kDa) in the
Published: 01 September 2004
Proteome Science 2004, 2:5 doi:10.1186/1477-5956-2-5
Received: 02 March 2004
Accepted: 01 September 2004
This article is available from: http://www.proteomesci.com/content/2/1/5
© 2004 Schweigert et al; licensee BioMed Central Ltd. 
This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Proteome Science 2004, 2:5 http://www.proteomesci.com/content/2/1/5
Page 2 of 6
(page number not for citation purposes)
kidneys. Any TTR or RBP molecules that are filtered are
rapidly bound to megalin, the multiligand receptor
expressed on the luminal surface of the renal proximal
tubules and therefore internalized. Thus, under physio-
logical conditions, TTR and RBP are present in urine if at
all, only in trace amounts [6].
The TTR variants described thus far have mostly been asso-
ciated with variable degrees of cardiac and/or neural tissue
amyloid deposits [7,8]. Therefore, mutations of the amino
acid sequence of TTR are of clinical interest [9]. In general,
mutations appear to be distributed randomly within the
molecule and most of these mutations lead to the synthe-
sis of TTR molecules which have the tendency to form
insoluble protein aggregates. These so-called amyloid
deposits accumulate extracellularly in various organs.
Although the role of amyloid deposits in the pathogenesis
of the disease is not clear, preventing their formation or
promoting their disaggregation is necessary to control the
development of clinical symptoms [10,11].
With regard to nutrition, TTR is a so-called visceral protein
that is synthesized in the liver in response to nutritional
supply. TTR plasma levels have thus been proposed as
sensitive biochemical parameters of subclinical protein
malnutrition, because both the adequacy and levels of
protein as well as energy intakes are reflected in plasma
levels. Plasma levels of TTR, however, are as well affected
by acute and chronic diseases associated with an acute-
phase response. Under these conditions, liver activity is
converted to the synthesis of acute-phase response pro-
teins, resulting in a dramatic drop in visceral proteins,
despite nutritional support [1-3].
This study was conducted to establish a sensitive and
reproducible high-throughput SELDI-TOF-MS immu-
noassay for characterizing TTR variants in plasma and
urine arising from amino acid substitutions, posttransla-
tional modifications and/or products of protein degrada-
tion or proteolysis.
Results
TTR levels in plasma and urine
TTR levels in plasma determined by ELISA in 10 healthy
individuals were 489 ± 155 µg/ml. TTR levels in urine of
the healthy individuals were one thousand times lower
than in the 40 pregnant women with 46 ± 24 ng/g creati-
nine and 45 ± 65 µg/g creatinine, respectively.
TTR microheterogeneity in plasma and urine
In Figure 1 the TTR variants found in serum and in urine
of pregnant women and non-pregnant controls were com-
pared using the Western blot technique. The results
obtained with this method showed that TTR was present
in plasma of both groups and in urine of pregnant women
but not in the urine of non-pregnant individuals. The
intensity of the immunoreactive band in urine of preg-
nant women was substantially lower than that in plasma.
In all investigated TTR-positive plasma and urine samples
TTR was present as a single band indicating a molecular
weight of 14 kDa.
SELDI-TOF-MS immunoassays showed that in healthy
non-pregnant and pregnant females as well as in males
TTR in plasma occurred rather consistently in two major
variants of 13732 ± 12 and 13851 ± 9 Da, of which gener-
ally the 13851 Da variant is the dominant one. The mass
difference between these two variant was 120 ± 9 Da. In
addition to the two major signals a minor one at 14043 ±
17 Da was observed in plasma. The mass difference to the
signal at 13851 Da was 192 ± 11 Da. In urine, traces of
TTR were detected in samples from non-pregnant females
and from males. In the urine of pregnant women however
strong mass signals were observed. As shown in Figure 2c,
the variant of 13736 ± 10 Da also present in plasma, as
well as lower molecular immunoreactive species were
observed at 12847 ± 29, 12984 ± 7, 13202 ± 16, 13349 ±
15 and 13575 ± 15 Da. In urine, although the TTR pattern
was different to the one in plasma, there were similarities
in all samples in which TTR was present.
Discussion
The SELDI platform can be readily adapted for developing
an immunoassay format. This approach, using antibodies
as an affinity capture device has been successfully used to
detect and quantify different proteins by MS in complex
biological mixtures [12]. Unlike current ELISA technology
that uses an indirect detection mechanism by "sandwich-
ing" the targeted protein with antibodies, the SELDI-
based immunoaffinity assay allows for direct detection
without tags. The specificity of the mass spectrometry
immunoassay is unsurpassed because there is the
Western blot of TTR in paired plasma (A) and urine (B) of  seven (1–7) healthy individuals and in seven urine samples  (C) of healthy pregnant women Figure 1
Western blot of TTR in paired plasma (A) and urine (B) of 
seven (1–7) healthy individuals and in seven urine samples 
(C) of healthy pregnant women. S = TTR standardProteome Science 2004, 2:5 http://www.proteomesci.com/content/2/1/5
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combined discriminating power of both the antibody and
the high molecular weight accuracy of the detector. In
terms of sensitivity, the detection limit can approach that
of current assays for TTR. The antibody used as bait recog-
nizes an epitope in different isoforms of TTR. This direct
sampling is a unique advantage over the more traditional
ELISA methods in which the resulting signal is a weighted
average of all the bound species. The discriminating
power of the assay is shown in the direct comparison
between Western blotting (Figure 1) and SELDI-TOF-MS
immunoassay (Figure 2). The small mass differences
observed with mass spectrometry can not be resolved by
the combination of electrophoresis and immunological
detection.
Mass spectra resulting from SELDI-TOF-MS immunoaffinity analysis of three (1–3) paired plasma (A) and urine (B) samples  obtained from healthy individuals (a) and three urine samples (C) from healthy pregnant women Figure 2
Mass spectra resulting from SELDI-TOF-MS immunoaffinity analysis of three (1–3) paired plasma (A) and urine (B) samples 
obtained from healthy individuals (a) and three urine samples (C) from healthy pregnant women.
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The results support and confirm previous studies with
regard to molecular variants of TTR in plasma and urine
[13-15]. As in these studies, TTR in plasma was dominant
in two variants. The 120 Da larger variant is the S-cystei-
nylated form of TTR. The inconsistently present smaller
signal at 14043 Da can be attributed to the S-glutathio-
nylated form of TTR [13,16,17]. Other forms due to dehy-
dration, or phosphorylation were not observed. The
reported isoforms of TTR result when the Cys10 residue
makes a mixed disulfide with the amino acid cysteine, the
peptide glutathione or the peptide cysteinyl-glycine.
Recent studies show that the most prevalent modification
of TTR renders it substantially more amyloidogenic than
the non-cysteinylated form at pH 5 [18]. The possible
importance as a risk factor for the onset of senile systemic
amyloidosis remains to be elucidated. Additionally, the S-
homocysteinylation of TTR has been described in plasma
of humans with hyperhomocysteinemia [19]. These two
aspects might support the importance of a diagnostic
approach to characterize isoforms of TTR more easily.
Apart from the case of absence, some modifications might
not be detected with this method due to limitations in res-
olution. Both methods, ELISA and SELDI immunoassay
are sensitive enough to observe only trace amounts of TTR
in body fluids as in the case of urine of healthy individu-
als. These amounts were not detected using immunoblot-
ting. Despite the small signal it was obvious that
additional variants to the ones in plasma are present in
urine. Contrary to a pervious study using a different
method [14] we were not able to observe the cysteinylated
form of TTR in urine despite being the dominant one in
paired plasma samples. Major differences to this method
are the possibility of one step on chip-enrichment and the
analysis of much smaller sample amounts but a lower
mass resolution. This latter aspect however, can not
explain these differences.
No study is available in which TTR has been described
quantitatively in the urine of healthy individuals. In this
study we are able to show for the first time that levels of
TTR in urine of pregnant women are 1000-fold higher
compared to the levels in urine of healthy non-pregnant
individuals. The excretion of substantial amounts of TTR
has only been described in individuals with different kid-
ney diseases indicating disturbed glomerular filtration
and/or insufficient tubular reabsorption [13]. The
involvement of the megalin receptor in the tubular reab-
sorption of filtered TTR has been shown in patients with
Dent's disease [6].
Interestingly, as shown by us also for the first time, TTR in
the urine of pregnant women is present in different
molecular variants. In contrast to plasma, the S-cystei-
nylated form dominant in plasma was if at all present
only in trace amounts. It remains to be determined if this
is limited to the excretion of TTR in pregnancy or if under
other circumstances such as in different kidney diseases
similar molecular variants occur as well. The lower
molecular weight immunoreactive variants found in urine
of pregnant women may arise from limited proteolysis. At
this point it is not possible to determine location and
extent of proteolysis within the molecule. The immunore-
active fragments might arise from a breakdown within the
plasma or the kidney structures.
Conclusions
The SELDI immunoaffinity-isolation of TTR in combina-
tion with mass spectrometry offers a rapid, highly repro-
ducible and cost-effective system for the determination of
molecular variants of microheterogenous proteins and
peptides. This is of importance in "second phase" pro-
teomics which is characterized by the repetitive investiga-
tion of the same protein to validate the protein phenotype
in large population based studies. This provides the basis
for a substantial progress in the diagnostic with regard to
personalized medicine [20,21]. With regard to TTR, this
approach might not only be of importance in the diagno-
sis of TTR related amyloidosis but may also have the
potential as alternative or new biomarkers related to the
metabolism of TTR for use in nutrition related disease as
well as in the diagnosis of kidney function.
Methods
Participants
Paired plasma and urine samples from 10 healthy individ-
uals were obtained. The plasma was prepared by centrifu-
gation of the blood (1500 × g, 10 min, 4°C) within 1–3 h
after acquisition. Additionally, urine samples of the ten
individuals and of healthy pregnant women (n = 40)
undergoing routine medical examination, were collected
and immediately mixed with protease inhibitors (Sigma,
Deisenhofen, Germany). Hematuria was tested using a
routine dipstick method (Combur 9 Test, Roche, Basel,
Switzerland). Cells and other non-soluble material were
cleared from the sample by brief centrifugation (1500 × g,
2 min). Aliquots of centrifuged urine were stored at -80°C
and processed as soon as possible. The study protocol was
approved by the hospitals and University of Potsdam Eth-
ics Committee. Informed consent was obtained from each
participant.
Determination of TTR using ELISA and Western blotting
Polyclonal antibodies to TTR were produced in rabbit and
affinity purified (Dako Diagnostics, Hamburg, Germany).
TTR in plasma and urine was quantitatively determined
by an enzyme-linked immunoassay (ELISA) method
developed in our laboratory. To further assess the pres-
ence of TTR quantitatively and qualitatively, weProteome Science 2004, 2:5 http://www.proteomesci.com/content/2/1/5
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performed a SDS-polyacrylamide gel electrophoresis
(PAGE) immunoblot analysis as has been described [22].
Immuno SELDI-TOF-MS
Protein A (Sigma, Deisenhofen, Germany) at 0.1 mg/ml
in PBS was added (5 µl) to the spots of a pre-activated Pro-
teinChip® Array (PS20; Ciphergen Biosystems Inc., Palo
Alto CA, USA). The PS20 array consists of a surface with
epoxy groups that dock proteins by covalently reacting
with their amine groups. The arrays were incubated for 1
h at 25°C in a humidity chamber. After blocking residual
active sites with 5 µl blocking buffer (0.5 M ethanolamine
in PBS at pH 8.0) for 25 min, the array was washed three
times in a 15 ml conical tube with PBS (pH 7.4). TTR anti-
body (4.1 µg/µl) was added to individual spots (2 µl) and
incubated in a humidity chamber for 1.5 h with mixing.
The unbound antibodies were removed by washing the
array three times in a 15 ml conical tube with PBS (pH
7.4).
Before incubation urine was diluted 1:1 (v:v) in PBS and
plasma 1:100 (v:v) in PBS. A total volume of 10 µl was
applied to each spot and incubated for 1.5 h at 25°C in a
humidity chamber. Samples were washed on the spot
with 5 µl PBS three times and finally with 5 µl H2O. After
drying, 0.6 µl of a saturated energy-absorbing molecule
(EAM) solution (5 mg sinapinic acid dissolved in 75 µl
acetonitrile and 75 µl 1% trifluoroacetic acid) was applied
to the spot surface, and the sample was allowed to dry.
After insertion of the ProteinChip Array into the Protein-
Chip Reader, a laser pulse was focused on the sample
under vacuum. The array was analyzed under the follow-
ing settings: laser intensity 250/220, detector sensitivity 8,
mass focus, molecular mass range 10 to 18 kDa, position
20–80 and a 150–200-shot average per sample.
CytochromeC (equine cardiac; 12360.1 MW), myoglobin
(equine cardiac; 16951.5 MW), GAPDH (rabbit; 35688
MW), albumin (bovine serum; 66433MW) and β-galac-
tosidase (E. coli; 116351MW) were used as calibrators.
Mass resolution (defined as m/∆m) is routinely achieved
below 300 and mass accuracy was within 0.1%. Peaks
with amplitudes at least 3 times greater than the average
background noise level were considered. The reproduci-
bility was tested with different aliquots of the same sam-
ple on eight different spots of the protein chip array.
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